MMP-12 blockade in B lymphocytes inhibits the formation of inducible BALTs and alleviates neutrophilic allergic airway inflammation
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115706 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Xijie Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: B-Lymphocytes, Asthma, Matrix Metalloproteinase 12, Neutrophils. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Inducible bronchus-associated lymphoid tissue (iBALT), the tertiary immune organ in the lungs, has been implicated in various pulmonary diseases. The formation and roles of iBALTs in neutrophilic allergic asthma, however, remain largely unexplored. In our study, iBALTs were located near bronchi and vessels in a neutrophilic asthma murine model induced by house dust mite (HDM) extract and lipopolysaccharide (LPS). Repeated sensitization promoted the formation of iBALTs, which disappeared 2 weeks after the last HDM challenge. We disrupted the function of B-cell chemokines (C-X-C motif chemokine ligand 13, CXCL13). The CXCL13 neutralizing antibody prevented the formation of iBALTs but failed to relieve airway inflammation. Bulk RNA-seq revealed elevated MMP-12 in pulmonary B lymphocytes, a major population in iBALTs. MMP408, a specific MMP-12 inhibitor, reduced iBALT formation. Moreover, a modified AAV-6 (adeno-associated virus-6) targeting MMP-12 in B lymphocytes blocked iBALTs and ameliorated neutrophilic airway inflammation. These results indicate that MMP-12 produced by B lymphocytes promotes the aggregation of B lymphocytes, promotes the formation of iBALTs, and further exacerbates inflammation in neutrophilic allergic asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: jiningfei@163.com.
- Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address: hm6114@163.com.
- Jiangsu Province Engineering Research Center of Antibody Drug, NHC Key Laboratory of Antibody Technique, Department of Immunology, Nanjing Medical University, Nanjing, China. Electronic address: mingshunzhang@njmu.edu.c…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Zhang, X., Yang, C., Wang, M., Yuan, Q., Jia, X., Xu, T., Wang, Z., Ji, N., Huang, M., & Zhang, M. (2025). MMP-12 blockade in B lymphocytes inhibits the formation of inducible BALTs and alleviates neutrophilic allergic airway inflammation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115706
Vancouver
Zhang X, Yang C, Wang M, Yuan Q, Jia X, Xu T, et al. MMP-12 blockade in B lymphocytes inhibits the formation of inducible BALTs and alleviates neutrophilic allergic airway inflammation. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115706
BibTeX
@article{Zhang2025,
author = {Zhang, Xijie and Yang, Chen and Wang, Min and Yuan, Qi and Jia, Xinyu and Xu, Tingting and Wang, Zhengxia and Ji, Ningfei and Huang, Mao and Zhang, Mingshun},
title = {MMP-12 blockade in B lymphocytes inhibits the formation of inducible BALTs and alleviates neutrophilic allergic airway inflammation},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115706}
}
EUVIMED